A New Model for Funding Cost-Effectiveness Research
Patients before profits
Public Good Pharma (PGP) is a platform providing clinical trials as a pharmaceutical cost-containment solution for health insurers by conducting self-funding “Interventional Pharmacoeconomic” (IVPE) clinical trials that compare low-cost alternatives to high-cost specialty drugs (e.g. repurposed generic drugs / biosimilars, nutraceuticals, diets and lifestyle interventions).
By conducting rigorous IVPE trials under the oversight of regulatory agencies, ethics committees, and our international Contract Research Organization (CRO) partners, we generate valuable clinical data to support reimbursement of the most cost-effective therapies without financial or legal risk to health insurers. This model drives rapid, sustainable innovation, significantly reduces healthcare costs, and expands patient access to high-value, affordable care.
Reduce Financial Toxicity
Improve Patient Outcomes
Unlike traditional pharma pursuing the inefficient and unsustainable “blockbuster drug” model, we find and clinically-validate low-cost alternatives to high-cost drugs. This means our interests are aligned with patients and health insurers because we earn revenue from conducting self-funding IVPE trials. Our eventual goal is to seek FDA approval for these low-cost therapies.
We work with aligned health insurers including self-insured employers, pass-through PBMs, state health plans and integrated health systems looking for an innovative way to manage specialty drug spend.
Get in touch today if you are interested in finding out how to reduce pharmaceutical spend while addressing the “financial toxicity” of new medicines.
